193 related articles for article (PubMed ID: 9004050)
21. Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs).
Ravizza L; Barzega G; Bellino S; Bogetto F; Maina G
Psychopharmacol Bull; 1996; 32(1):167-73. PubMed ID: 8927668
[TBL] [Abstract][Full Text] [Related]
22. Effects of acute intravenous clomipramine on obsessive-compulsive symptoms and response to chronic treatment.
Mundo E; Bellodi L; Smeraldi E
Biol Psychiatry; 1995 Oct; 38(8):525-31. PubMed ID: 8562664
[TBL] [Abstract][Full Text] [Related]
23. [Pharmacotherapy of compulsive disorders in childhood and adolescence].
Wewetzer Ch; Mehler-Wex C; Warnke A
Z Kinder Jugendpsychiatr Psychother; 2003 Aug; 31(3):223-30. PubMed ID: 12942794
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review.
Piccinelli M; Pini S; Bellantuono C; Wilkinson G
Br J Psychiatry; 1995 Apr; 166(4):424-43. PubMed ID: 7795913
[TBL] [Abstract][Full Text] [Related]
25. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial.
Goodman WK; Kozak MJ; Liebowitz M; White KL
Int Clin Psychopharmacol; 1996 Mar; 11(1):21-9. PubMed ID: 8732310
[TBL] [Abstract][Full Text] [Related]
26. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
[TBL] [Abstract][Full Text] [Related]
27. Effect of acute intravenous clomipramine and antiobsessional response to proserotonergic drugs: is gender a predictive variable?
Mundo E; Bareggi SR; Pirola R; Bellodi L
Biol Psychiatry; 1999 Feb; 45(3):290-4. PubMed ID: 10023504
[TBL] [Abstract][Full Text] [Related]
28. A clomipramine dosage reduction study in the course of long-term treatment of obsessive-compulsive disorder patients.
Pato MT; Hill JL; Murphy DL
Psychopharmacol Bull; 1990; 26(2):211-4. PubMed ID: 2236458
[TBL] [Abstract][Full Text] [Related]
29. Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression.
Apter A; Ratzoni G; King RA; Weizman A; Iancu I; Binder M; Riddle MA
J Am Acad Child Adolesc Psychiatry; 1994; 33(3):342-8. PubMed ID: 8169178
[TBL] [Abstract][Full Text] [Related]
30. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial.
Ninan PT; Koran LM; Kiev A; Davidson JR; Rasmussen SA; Zajecka JM; Robinson DG; Crits-Christoph P; Mandel FS; Austin C
J Clin Psychiatry; 2006 Jan; 67(1):15-22. PubMed ID: 16426083
[TBL] [Abstract][Full Text] [Related]
31. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
Erzegovesi S; Guglielmo E; Siliprandi F; Bellodi L
Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
[TBL] [Abstract][Full Text] [Related]
32. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.
Bogetto F; Bellino S; Vaschetto P; Ziero S
Psychiatry Res; 2000 Oct; 96(2):91-8. PubMed ID: 11063782
[TBL] [Abstract][Full Text] [Related]
33. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder.
Denys D; van der Wee N; van Megen HJ; Westenberg HG
J Clin Psychopharmacol; 2003 Dec; 23(6):568-75. PubMed ID: 14624187
[TBL] [Abstract][Full Text] [Related]
34. Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial.
Esalatmanesh S; Abrishami Z; Zeinoddini A; Rahiminejad F; Sadeghi M; Najarzadegan MR; Shalbafan MR; Akhondzadeh S
Psychiatry Clin Neurosci; 2016 Nov; 70(11):517-526. PubMed ID: 27488081
[TBL] [Abstract][Full Text] [Related]
35. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD).
Haghighi M; Jahangard L; Mohammad-Beigi H; Bajoghli H; Hafezian H; Rahimi A; Afshar H; Holsboer-Trachsler E; Brand S
Psychopharmacology (Berl); 2013 Aug; 228(4):633-40. PubMed ID: 23525525
[TBL] [Abstract][Full Text] [Related]
36. Intravenous Clomipramine for Treatment-Resistant Obsessive-Compulsive Disorder.
Karameh WK; Khani M
Int J Neuropsychopharmacol; 2015 Jul; 19(2):. PubMed ID: 26221004
[TBL] [Abstract][Full Text] [Related]
37. Clomipramine demethylation rate is important on the outcome of obsessive-compulsive disorder treatment.
Marcourakis T; Bernik MA; Lotufo Neto F; Gedanke Shavitt R; Gorenstein C
Int Clin Psychopharmacol; 2015 Jan; 30(1):43-8. PubMed ID: 25279584
[TBL] [Abstract][Full Text] [Related]
38. Predictive value of obsessive-compulsive personality disorder in antiobsessional pharmacological treatment.
Cavedini P; Erzegovesi S; Ronchi P; Bellodi L
Eur Neuropsychopharmacol; 1997 Feb; 7(1):45-9. PubMed ID: 9088884
[TBL] [Abstract][Full Text] [Related]
39. Relapses after discontinuation of drug associated with increased resistance to treatment in obsessive-compulsive disorder.
Maina G; Albert U; Bogetto F
Int Clin Psychopharmacol; 2001 Jan; 16(1):33-8. PubMed ID: 11195258
[TBL] [Abstract][Full Text] [Related]
40. Open trial of intravenous clomipramine in five treatment-refractory patients with obsessive-compulsive disorder.
Fallon BA; Campeas R; Schneier FR; Hollander E; Feerick J; Hatterer J; Goetz D; Davies S; Liebowitz MR
J Neuropsychiatry Clin Neurosci; 1992; 4(1):70-5. PubMed ID: 1627966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
